Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis

被引:230
|
作者
Ardizzone, Sandro [1 ]
Cassinotti, Andrea [1 ]
Duca, Piergiorgio [2 ]
Mazzali, Cristina [2 ]
Penati, Chiara [1 ]
Manes, Gianpiero [1 ]
Marmo, Riccardo [3 ]
Massari, Alessandro [1 ]
Molteni, Paola [1 ]
Maconi, Giovanni [1 ]
Porro, Gabriele Bianchi [1 ]
机构
[1] L Sacco Univ Hosp, Gastroenterol Unit, Dept Clin Sci, Milan, Italy
[2] L Sacco Univ Hosp, Sect Med Stat & Biometry, Milan, Italy
[3] Azienda Sanit Locale Salerno, Unita Operat Gastroenterol Polla, Salerno, Italy
关键词
Inflammatory Bowel Diseases; Endoscopy; Clinical Course; Mucosal Healing; INFLAMMATORY-BOWEL-DISEASE; POPULATION-BASED COHORT; NATURAL-HISTORY; THERAPY; RELAPSE; PROCTOCOLITIS; PARAMETERS; COLECTOMY; GENDER; RISK;
D O I
10.1016/j.cgh.2010.12.028
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: It is uncertain whether mucosal healing after the first course of corticosteroids therapy predicts outcome in patients with ulcerative colitis (UC). We evaluated whether early clinical and endoscopic responses to this therapy are associated with late outcomes in UC. METHODS: Patients with newly diagnosed UC who were prescribed corticosteroid therapy (n = 157) were followed up for 5 years. They were evaluated using clinical (Powel-Tuck [PT]) and endoscopic (Baron) indexes after 3 and 6 months, then every 6 months. Outcomes at month 3 (early response) were used to identify patients with complete (group A: PT, 0-1; Baron, 0), partial (group B: PT, 0-1; Baron, 1-3), or no response (group C: persistence of clinical and endoscopic activity). The association between early and late outcomes was assessed. RESULTS: After 5 years, there were significant differences between complete and partial responders in the rates of hospitalization (25% in group A vs 48.7% in group B; P = .0152; odds ratio [OR], 2.85; 95% confidence interval [CI], 1.21-6.72), immunosuppression therapy (5% in group A vs 25.6% in group B; P = .0030; OR, 6.55; 95% CI, 1.67-25.67), colectomy (3.3% in group A vs 18.0% in group B; P = .0265; OR, 6.34; 95% CI, 1.24-32.37), and their combination (26.7% in group A vs 48.7% in group B; P = .0249; OR, 2.61; 95% CI, 1.12-6.11). After multivariate analysis, lack of mucosal healing was the only factor associated with negative outcomes at 5 years (immunosuppressors: hazard risk [HR], 10.581; 95% CI, 2.193-51.039; P = .0033; hospitalization: HR, 3.634; 95% CI, 1.556-8.485; P = .0029; colectomy: HR, 8.397; 95% CI, 1.278-55.186; P = .0268). CONCLUSIONS: No mucosal healing after corticosteroid therapy is associated with a more aggressive disease course.
引用
收藏
页码:483 / U117
页数:10
相关论文
共 50 条
  • [1] Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis
    Theede, Klaus
    Holck, Susanne
    Ibsen, Per
    Kallemose, Thomas
    Nordgaard-Lassen, Inge
    Nielsen, Anette Mertz
    INFLAMMATORY BOWEL DISEASES, 2016, 22 (05) : 1042 - 1048
  • [2] Factors Associated With Poor Outcomes in Adults With Newly Diagnosed Ulcerative Colitis
    Reinisch, Walter
    Reinink, Andrew R.
    Higgins, Peter D. R.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2015, 13 (04) : 635 - 642
  • [3] Prevalence of Corticosteroids Use and Disease Course After Initial Steroid Exposure in Ulcerative Colitis
    Khan, Nabeel
    Abbas, Ali
    Williamson, Alice
    Balart, Luis
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (10) : 2963 - 2969
  • [4] Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids
    Bello, C.
    Belaiche, J.
    Louis, E.
    Reenaers, C.
    JOURNAL OF CROHNS & COLITIS, 2011, 5 (03) : 196 - 202
  • [5] The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis
    Magnusson, Maria K.
    Strid, Hans
    Isaksson, Stefan
    Simren, Magnus
    Ohman, Lena
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (06) : 956 - 966
  • [6] Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
    Colombel, Jean Frederic
    Rutgeerts, Paul
    Reinisch, Walter
    Esser, Dirk
    Wang, Yanxin
    Lang, Yinghua
    Marano, Colleen W.
    Strauss, Richard
    Oddens, Bjoern J.
    Feagan, Brian G.
    Hanauer, Stephen B.
    Lichtenstein, Gary R.
    Present, Daniel
    Sands, Bruce E.
    Sandborn, William J.
    GASTROENTEROLOGY, 2011, 141 (04) : 1194 - 1201
  • [7] Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes
    Pandey, Anuja
    Achrafie, Lea
    Kodjamanova, Petya
    Tencer, Tom
    Kumar, Jinender
    CURRENT MEDICAL RESEARCH AND OPINION, 2022, 38 (09) : 1531 - 1541
  • [8] Imaging in Inflammatory Bowel Disease Mucosal Healing in Ulcerative Colitis: Relevance for Clinical Outcomes
    Schirbel, Anja
    Sturm, Andreas
    CURRENT DRUG TARGETS, 2012, 13 (10) : 1234 - 1244
  • [9] Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids
    Garcia-Planella, Esther
    Manosa, Miriam
    Van Domselaar, Manuel
    Gordillo, Jordi
    Zabana, Yamile
    Cabre, Eduard
    Lopez San Roman, Antonio
    Domenech, Eugeni
    DIGESTIVE AND LIVER DISEASE, 2012, 44 (03) : 206 - 210
  • [10] Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis
    Wen, Yunling
    Niu, Junkun
    Zhang, Fengrui
    Wu, Jing
    Li, Maojuan
    Sun, Yang
    Wang, Wen
    Xia, Shuxian
    Tan, Ying
    Wang, Kunhua
    Miao, Yinglei
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 677 - 686